“This collaboration provides an excellent platform to make K101 the leading product for treatment of nail fungus in the Nordic countries. Our new partner has an impressive track record in promotion of non-prescription products and the resources and capabilities to successfully promote K101", says Moberg Derma's President and CEO, Peter Wolpert. "This deal also enables Moberg Derma to build its Nordic market organisation in collaboration with a strong partner.”
About K101 and nail fungus K101 has the potential to become first-line treatment for nail fungus. The safety and efficacy of K101 was recently demonstrated in a phase III trial, in which 494 patients were treated during six months with K101 or a placebo. In the trial, significantly more patients receiving K101 were cured of their fungal infection (p=0.001). In addition, the proportion of patients who considered that their condition had improved was significantly larger among patients treated with K101 at all follow-up time points. Nail fungus is a common condition and afflicts 8-14% of the general population. Since many patients do not seek treatment, the untapped market potential is significant and there is a considerable need for new and efficacious topical treatments. The estimated market exceeds USD 1 billion.
Contact Moberg Derma Peter Wolpert, President and CEO Telephone: +46 8 522 307 08 Mobile: +46 70 735 71 35 E-mail: peter.wolpert@mobergderma.se
About Moberg Derma Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of common skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining promotion rights for the Nordic region. The company began operations at the Karolinska Institute in 2006 and currently has 10 employees. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se
